|Classification and external resources|
Anovulation is when the ovaries do not release an oocyte during a menstrual cycle. Therefore, ovulation does not take place. However, a woman who does not ovulate at each menstrual cycle is not necessarily going through menopause. Chronic anovulation is a common cause of infertility.
In addition to the alteration of menstrual periods and infertility, chronic anovulation can cause or exacerbate other long term problems, such as hyperandrogenism or osteopenia. It plays a central role in the multiple imbalances and dysfunctions of polycystic ovary syndrome.
During the first two years after menarche 50% of the menstrual cycles could be anovulatories.
It is in fact possible to restore ovulation using appropriate medication, and ovulation is successfully restored in approximately 90% of cases. The first step is the diagnosis of anovulation. The identification of anovulation is not easy; contrary to what is commonly believed, women undergoing anovulation still have (more or less) regular periods. In general, patients only notice that there is a problem once they have started trying to conceive.
Temperature charting is a useful way of providing early clues about anovulation, and can help gynaecologists in their diagnosis.
- 1 Classification
- 2 Causes
- 3 Detection
- 4 Treatments
- 5 Associated conditions
- 6 References
The World Health Organization criteria for classification of anovulation include the determination of oligomenorrhea (menstrual cycle >35 days) or amenorrea (menstrual cycle > 6 months) in combination with concentration of prolactin, follicle stimulating hormone (FSH) and estradiol (E2). The patients are classified as WHO1 (15%) - hypo-gonadotropic, hypo-estrogenic, WHO2 (80%) - normo-gonadotropic, normo-estrogenic, and WHO3 (5%) - hyper-gonadotropic, hypo-estrogenic. The vast majority of anovulation patients belong to the WHO2 group and demonstrate very heterogeneous symptoms ranging from anovulation, obesity, biochemical or clinical hyperandrogenism and insulin resistance.
Hormonal or chemical imbalance
This is the most common cause of anovulation and is thought to account for about 70% of all cases. About half the women with hormonal imbalances do not produce enough follicles to ensure the development of an ovule, possibly due to poor hormonal secretions from the pituitary gland or the hypothalamus. The pituitary gland controls most other hormonal glands in the human body. Therefore, any pituitary malfunctioning affects other glands under its influence, including the ovaries. This occurs in around 10% of cases. The mammary glands are also controlled by the pituitary gland, so lactation can also be affected. The pituitary gland is controlled by the hypothalamus. In 10% of cases, alterations in the chemical signals from the hypothalamus can easily seriously affect the ovaries.
There are other hormonal anomalies with no direct link to the ones mentioned above that can affect ovulation. For instance, women with hyper or hypo-thyroidism sometimes have ovulation problems. Thyroid dysfunction can halt ovulation by upsetting the balance of the body’s natural reproductive hormones. Polycystic ovary syndrome (also known as Stein-Leventhal syndrome) and hyperprolactinemia can also cause anovulatory cycles through hormonal imbalances.
This accounts for around 10-15% of all cases of anovulation. The ovaries can stop working in about 5% of cases. This may be because the ovaries do not contain eggs. However, a complete blockage of the ovaries is rarely a cause of infertility. Blocked ovaries can start functioning again without a clear medical explanation. In some cases, the egg may have matured properly, but the follicle may have failed to burst (or the follicle may have burst without releasing the egg). This is called luteinised unruptured follicle syndrome (LUFS). Physical damage to the ovaries, or ovaries with multiple cysts, may affect their ability to function. This is called ovarian dystrophy. Patients who are suffering from Stein-Leventhal syndrome (also referred to as polycystic ovary syndrome, or PCOS) can also suffer from anovulation. Up to 90% of cases of anovulation are caused by PCOS; this syndrome is usually hereditary.
Weight loss or anorexia can also cause hormonal imbalance, leading to irregular ovulation (dysovulation). It is possible that this mechanism evolved to protect the mother’s health. A pregnancy where the mother is weak could pose a risk to the baby’s and mother’s health. On the other hand, excess weight can also create ovarian dysfunctions. Dr Barbieri of Harvard Medical School has indicated that cases of anovulation are quite frequent in women with a BMI (body mass index) over 27 kg/m2. Unfortunately, not only does excess weight have a negative impact on ovulation itself, but also on treatment efficacy and outcomes of ART (assisted reproductive technique).
Signs and symptoms
Anovulation is usually associated with specific symptoms. However, it is important to note that they are not necessarily all displayed simultaneously. Amenorrhea (absence of menstruation) occurs in about 20% of women with ovulatory dysfunction. Infrequent and light menstruation occurs in about 40% of women with ovulatory dysfunction. Another potential symptom is irregular menstruation, where five or more menstrual cycles a year are five or more days shorter or longer than the length of the average cycle. Absence of mastodynia (breast pain or tenderness) occurs in about 20% of women with ovulatory problems. Also possible is increased body mass and facial hair, which is relatively easy to treat, and is often associated with PCOS, or polycystic ovary syndrome.
Fertility awareness and LH measurement
Symptoms-based methods of fertility awareness may be used to detect ovulation or to determine that cycles are anovulatory. Charting of the menstrual cycle may be done by hand, or with the aid of various fertility monitors. Records of one of the primary fertility awareness signs—basal body temperature—can detect ovulation by identifying the shift in temperature which takes place after ovulation. It is said to be the most reliable way of confirming whether ovulation has occurred.
Women may also use ovulation predictor kits (OPKs) which detect the increase in luteinizing hormone (LH) levels that usually indicates imminent ovulation. For some women, these devices do not detect the LH surge, or high levels of LH are a poor predictor of ovulation; this is particularly common in women with PCOS. In such cases, OPKs and those fertility monitors which are based on LH may show false results, with an increased number of false positives or false negatives. Dr Freundl from the University of Heidelberg suggests that tests which use LH as a reference often lack sensitivity and specificity.
The treatment of anovulation is termed ovulation induction and is usually quite efficient. The main treatments are clomifene citrate and gonadotropins.
Clomifene citrate (or clomid) is the medication which is most commonly used to treat anovulation. It is a selective estrogen-receptor modulator, affecting the hypothalamic–pituitary–gonadal axis to respond as if there was an estrogen deficit in the body, in effect increasing the production of gonadotrophins. It is relatively easy and convenient to use. Clomifene appears to inhibit estrogen receptors in hypothalamus, thereby inhibiting negative feedback of estrogen on gonadotrophin production. It may also result in direct stimulation of the hypothalamic-pituitary axis. It also has an effect on cervical mucus quality and uterine mucosa, which might affect sperm penetration and survival, hence its early administration during the menstrual cycle. Clomifene citrate is a very efficient ovulation inductor, and has a success rate of 67%. Nevertheless, it only has a 37% success rate in inducing pregnancy. This difference may be due to the anti-estrogenic effect which clomifene citrate has on the endometrium, cervical mucus, uterine blood flow, as well as the resulting decrease in the motility of the fallopian tubes and the maturation of the oocytes.
The standard dosage for first-time takers is 50 or 100 mg of clomifene per day for five consecutive days, starting early in the menstrual cycle, usually on the third to fifth day counting from the beginning of the menstrual period. In case of amenorrhea, a period can be induced by intake of an oral progestin for 10 days. In absence of success, the dosage can be increased in subsequent cycles with increments of 50 mg. However, at a dosage of 200 mg, further increments are unlikely to increase pregnancy chances.
Letrozole has been used for ovarian stimulation by fertility doctors since 2001 because it has fewer side-effects than clomiphene and less chance of multiple gestation. A study of 150 babies following treatment with letrozole or letrozole and gonadotropins presented at the American Society of Reproductive Medicine 2005 Conference found no difference in overall abnormalities but did find a significantly higher rate of locomotor and cardiac abnormalities among the group having taken letrozole compared to natural conception. A larger, follow-up study with 911 babies compared those born following treatment with letrozole to those born following treatment with clomiphene. That study also found no significant difference in the rate of overall abnormalities, but found that congenital cardiac anomalies was significantly higher in the clomiphene group compared to the letrozole group. Despite this, India banned the usage of letrozole in 2011, citing potential risks to infants. In 2012, an Indian parliamentary committee said that the drug controller office colluded with letrozole's makers to approve the drug for infertility in India and also stated that letrozole's use for infertility was illegal worldwide; however, such off-label uses are legal in many countries such as the US and UK.
Human chorionic gonadotropin (hCG) is a molecule which is structurally similar to luteinizing hormone (LH). LH is secreted by the pituitary just before ovulation occurs, whereas hCG is released during pregnancy. On its own, hCG is not very effective in inducing ovulation, but when combined with clomifene citrate, it is much more effective. The results associated with this method have been described as "quite encouraging". HCG should only be administered at certain points in the cycle, around the time of ovulation, and only if the infertility diagnostic has indicated that the problem is related to the release of the egg.
Human menopausal gonadotropin (hMG) is a very powerful treatment for infertility. It consists of a combination of LH and FSH. From menopause onwards, the body starts secreting LH and FSH in large quantities due to the slowing down of the ovarian function. This excess of hormones is not used by the body and is expelled in the urine. HMG is therefore collected from the urine of menopausal women. The urine then undergoes purification and a chemical treatment. The resulting hMG induces the stimulation of several ovarian follicles. This increases the risk of producing several oocytes during the same cycle, and thus the risk of multiple pregnancies.
Follicle-stimulating hormone (FSH or recombinant FSH) is now used as a replacement for hMG. Although hMG is a combination of FSH and LH, FSH is the only active component that has an effect on ovulation. However, until recently, it was not possible to produce pure FSH. FSH is now administered in a similar way as hMG, at a specific point during the cycle, and it requires medical monitoring. It is therefore important to fully understand a woman’s cycle, and to be able to accurately anticipate menstruation and ovulation dates. FSH is also sometimes useful for women who are suffering from PCOS.
Other treatments in anovulation
The gonadotropin-releasing hormone (GnRH) pump is used to release doses of GnRH in a pulsatile fashion. This hormone is synthesised by the hypothalamus and induces the secretion of LH and FSH by the pituitary. GnRH must be delivered in a pulsatile fashion to imitate the random secretion of the hypothalamus in order to fool the pituitary into secreting LH and FSH. The GnRH pump is the size of a cigarette box and has a small catheter. Unlike other treatments, using the GnRH pump doesn’t usually lead to multiple pregnancies. Filicori from the University of Bologna suggests that this might be because gonadotrophins are absent when the treatment is initiated, and therefore the hormones released by the pituitary (LH and FSH) can still take part in the retro-control of gonadotrophin secretion, mimicking the natural cycle. This treatment can also be used for underweight and/or anorexic patients; it has also been used in certain cases of hyperprolactimenia.
Tamoxifen affects estrogen receptors in a similar fashion as clomifene citrate. It is often used in the prevention and treatment of breast cancer. It can therefore also be used to treat patients that have a reaction to clomifene citrate.
Bromocriptine acts in a completely different manner to the other treatments mentioned above. It does not induce ovulation, but reduces the production of prolactin by the pituitary. Bromocriptine is only prescribed in cases of overproduction of prolactin (hyperprolactinemia).
Corticosteroids (usually found in anti-inflammatory drugs) can be used to treat anovulation if it is caused by an overproduction of male hormones by the adrenal glands. Corticosteroids are usually used to reduce the production of testosterone.
Several studies indicate that in some cases, a simple change in lifestyle could help patients suffering from anovulation. Consulting a nutritionist, for example, could help a young woman suffering from anorexia to put on some weight, which might restart her menstrual cycle. Conversely, a young overweight woman who manages to lose weight could also relieve the problem of anovulation (losing just 5% of body mass could be enough to restart ovulation). However, it is widely acknowledged by doctors that it is usually very difficult for PCOS patients to lose weight.
Previously, metformin was recommended as treatment for anovulation in polycystic ovary syndrome, but in the largest trial to date, comparing clomiphene with metformin, clomiphene was more effective than metformin alone. Following this study, the ESHRE/ASRM-sponsored Consensus workshop do not recommend metformin for ovulation stimulation. Subsequent randomized studies have confirmed the lack of evidence for adding metformin to clomiphene.
Prevention of multiple pregnancy
The European Society of Human Reproduction and Embryology (ESHRE) notes that the aim of ovulation induction should be mono-ovulation and not over-stimulation of the ovaries. The risks associated with multiple pregnancy are much higher than singleton pregnancy; incidences of perinatal death are seven times higher in triplet births and five times higher in twin births than the risks associated with a singleton pregnancy. It is therefore important to adapt the treatment to each individual patient.
Women with polycystic ovary syndrome may be particularly at risk. Multiple pregnancy occurs in approximately 15-20% of cases following cycles induced with gonadotrophins such as hMG and FSH induced ovulations.
During ovulation induction, it is recommended to start at a low dose and monitor the ovarian response with vaginal ultrasound, including discernment of the number of developing follicles. A cycle with supernumerary follicles is usually defined as one where there are more than two follicles >16 mm in diameter. It is generally recommended to have such cycles cancelled because of the risk of multiple pregnancy. In cancelled cycles, the woman or couple should be warned of the risks in case of supernumerary follicles, and should avoid sexual intercourse or use contraception until the next menstruation. Induction of final maturation (such as done with hCG) may need to be withheld because of increased risk of ovarian hyperstimulation syndrome(OHSS). The starting dose of the inducing drug should be reduced in the next cycle.
Alternatives to cancelling a cycle are mainly:
- Aspiration of supernumerary follicles until one or two remain.
- Converting the protocol to IVF treatment with embryo transfer of up to two embryos only.
- Selective fetal reduction. This alternative confers a high risk of complications.
- Proceeding with any multiple pregnancy without fetal reduction, with the ensuing risk of complications. This alternative is not recommended.
For most women, alteration of menstrual periods is the principal indication of chronic anovulation. Ovulatory menstrual periods tend to be regular and predictable in terms of cycle length, duration and heaviness of bleeding, and other symptoms. Ovulatory periods are often accompanied by midcycle symptoms such as mittelschmerz or premenstrual symptoms. In contrast, anovulation usually manifests itself as irregularity of menstrual periods, that is, unpredictable variability of intervals, duration, or bleeding. Anovulation can also cause cessation of periods (secondary amenorrhea) or excessive bleeding (dysfunctional uterine bleeding). Mittelschmerz and premenstrual symptoms tend to be absent or reduced when a woman is anovulatory.
- NADIR R. FARID; Evanthia Diamanti-Kandarakis (26 March 2009). Diagnosis and Management of Polycystic Ovary Syndrome. Springer. p. 243. ISBN 978-0-387-09717-6. Retrieved 5 September 2012.
- Legro RS (February 2007). "A 27-year-old woman with a diagnosis of polycystic ovary syndrome". JAMA. 297 (5): 509–519. doi:10.1001/jama.297.5.509. PMID 17284701.
- Alexander NB, Cotanch PH (September 1980). "The endocrine basis of infertility in women". Nurs. Clin. North Am. 15 (3): 511–24. PMID 6777763.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (January 2004). "Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome". Fertil. Steril. 81 (1): 19–25. doi:10.1016/j.fertnstert.2003.10.004. PMID 14711538.
- Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (June 2004). "The prevalence and features of the polycystic ovary syndrome in an unselected population". J. Clin. Endocrinol. Metab. 89 (6): 2745–2749. doi:10.1210/jc.2003-032046. PMID 15181052.
- Hull MG (September 1987). "Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies". Gynecol. Endocrinol. 1 (3): 235–245. doi:10.3109/09513598709023610. PMID 3140583.
- Barbieri RL (November 2001). "The initial fertility consultation: recommendations concerning cigarette smoking, body mass index, and alcohol and caffeine consumption". Am. J. Obstet. Gynecol. 185 (5): 1168–1173. doi:10.1067/mob.2001.117667. PMID 11717652.
- Filicori M, Flamigni C, Dellai P, et al. (October 1994). "Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles". J. Clin. Endocrinol. Metab. 79 (4): 1215–1220. doi:10.1210/jc.79.4.1215. PMID 7962297.
- Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC (July 1998). "Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility". J. Clin. Endocrinol. Metab. 83 (7): 2361–2365. doi:10.1210/jc.83.7.2361. PMID 9661609.
- Hamilton-Fairley D, Kiddy D, Watson H, Paterson C, Franks S (February 1992). "Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin". Br J Obstet Gynaecol. 99 (2): 128–31. doi:10.1111/j.1471-0528.1992.tb14470.x. PMID 1554664.
- Crosignani PG, Ragni G, Parazzini F, Wyssling H, Lombroso G, Perotti L (March 1994). "Anthropometric indicators and response to gonadotrophin for ovulation induction". Hum. Reprod. 9 (3): 420–3. PMID 8006129.
- Fedorcsák P, Storeng R, Dale PO, Tanbo T, Abyholm T (January 2000). "Obesity is a risk factor for early pregnancy loss after IVF or ICSI". Acta Obstet Gynecol Scand. 79 (1): 43–48. doi:10.1080/j.1600-0412.2000.079001043.x. PMID 10646815.[permanent dead link]
- Freundl G; Godehardt E; Kern PA; Frank-Herrmann P; Koubenec HJ; Gnoth Ch (December 2003). "Estimated maximum failure rates of cycle monitors using daily conception probabilities in the menstrual cycle". Hum. Reprod. 18 (12): 2628–2633. doi:10.1093/humrep/deg488. PMID 14645183.
- Freundl G, Bremme M, Frank-Herrmann P, Baur S, Godehardt E, Sottong U (June 1996). "The CUE Fertility Monitor compared to ultrasound and LH peak measurements for fertile time ovulation detection". Adv Contracept. 12 (2): 111–121. doi:10.1007/BF01849632. PMID 8863906.
- Lord JM, Flight IH, Norman RJ (October 2003). "Metformin in polycystic ovary syndrome: systematic review and meta-analysis". BMJ. 327 (7421): 951–0. doi:10.1136/bmj.327.7421.951. PMC . PMID 14576245.
- DrugBank > Clomifene. Updated on April 19, 2011
- Kousta E, White DM, Franks S (1997). "Modern use of clomiphene citrate in induction of ovulation". Hum. Reprod. Update. 3 (4): 359–365. doi:10.1093/humupd/3.4.359. PMID 9459281.
- Medications for Inducing Ovulation from American Society for Reproductive Medicine. Revised 2012.
- Biljan MM, Hemmings R, Brassard N (2005). "The Outcome of 150 Babies Following the Treatment With Letrozole or Letrozole and Gonadotropins". Fertility and Sterility. 84: S95. doi:10.1016/j.fertnstert.2005.07.230.
- Tulandi T, Martin J, Al-Fadhli R, et al. (June 2006). "Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate". Fertility and Sterility. 85 (6): 1761–5. doi:10.1016/j.fertnstert.2006.03.014. PMID 16650422.
- Sinha, Kounteya (18 October 2011). "Finally, expert panel bans fertility drug Letrozole". The Times of India. Retrieved 14 November 2011.
- "House panel to govt: Punish those guilty of approving Letrozole". The Times of India. 10 April 2007. Retrieved 9 May 2012.
- Chen DT, Wynia MK, Moloney RM, Alexander GC (2009). "Physician knowledge of the FDA-approved indications of commonly prescribed drugs: results of a national survey". Pharmacoepidemiology and Drug Safety. 18 (11): 1–7. doi:10.1002/pds.1825. PMID 19697444.
- "GMC | Good practice in prescribing medicines – guidance for doctors". Gmc-uk.org. 16 February 2007. Archived from the original on 19 December 2008. Retrieved 21 November 2011.
- Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R (2000). Nugent D, ed. "Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome". Cochrane Database Syst Rev (4): CD000410. doi:10.1002/14651858.CD000410. PMID 11034687.
- Braat DD, Schoemaker R, Schoemaker J (February 1991). "Life table analysis of fecundity in intravenously gonadotropin-releasing hormone-treated patients with normogonadotropic and hypogonadotropic amenorrhea". Fertil. Steril. 55 (2): 266–71. PMID 1991525.
- Boostanfar R, Jain JK, Mishell DR, Paulson RJ (May 2001). "A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction". Fertil. Steril. 75 (5): 1024–1026. doi:10.1016/S0015-0282(01)01749-6. PMID 11334921.
- Palomba S, Orio F, Nardo LG, et al. (October 2004). "Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial". J. Clin. Endocrinol. Metab. 89 (10): 4801–4809. doi:10.1210/jc.2004-0689. PMID 15472166.
- Legro RS, Barnhart HX, Schlaff WD (2007). "Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome". N Engl J Med. 356 (6): 551–566. doi:10.1056/NEJMoa063971. PMID 17287476.
- Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (March 2008). "Consensus on infertility treatment related to polycystic ovary syndrome". Fertil. Steril. 89 (3): 505–522. doi:10.1016/j.fertnstert.2007.09.041. PMID 18243179.
- Johnson NP, Stewart AW, Falkiner J, et al. (April 2010). "PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene". Hum Reprod. 25 (7): 1675–1683. doi:10.1093/humrep/deq100. PMID 20435692.
- Bergh T, Ericson A, Hillensjö T, Nygren KG, Wennerholm UB (November 1999). "Deliveries and children born after in-vitro fertilisation in Sweden 1982-95: a retrospective cohort study". Lancet. 354 (9190): 1579–1585. doi:10.1016/S0140-6736(99)04345-7. PMID 10560671.
- Fisk NM, Trew G (November 1999). "Two's company, three's a crowd for embryo transfer". Lancet. 354 (9190): 1572–1573. doi:10.1016/S0140-6736(99)00290-1. PMID 10560665.
- Eshre Capri Workshop Group (2003). "Mono-ovulatory cycles: a key goal in profertility programmes". Hum. Reprod. Update. 9 (3): 263–274. doi:10.1093/humupd/dmg020. PMID 12859047.
- Hong Kong College of Obstetricians and Gynaecologists > Guidelines for use of gonadotrophins- revised Archived September 9, 2012, at the Wayback Machine.. Number 1. April 2003.
- Albano, C.; Platteau, P.; Nogueira, D.; Cortvrindt, R.; Smitz, J.; Devroey, P. (2001). "Avoidance of multiple pregnancies after ovulation induction by supernumerary preovulatory follicular reduction". Fertility and Sterility. 76 (4): 820–822. doi:10.1016/S0015-0282(01)02379-2. PMID 11591420.